Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The most prevalent baseline PPO criteria were calcium and vitamin D supplement omission in patients with self-reported osteoporosis (ACOVE indicators and START, 14.7 %) and omission of a laxative in an older person with persistent pain treated with opioids (ACOVE indicators, 11.0 %).Prevalence of individual PIM criteria (prevalence ≥2 %) at baseline and 2-year follow-upCriteria descriptionBaselineFollow-up n % of sample% of indicationa n % of sample% of indicationa Change in prevalence (95 % CI)STOPP Cardiovascular system Loop diuretic for dependent ankle oedema only974.7 to 1145.6 to 0.8 (−0.6, 2.2) Aspirin with history of PUD without H2 receptor antagonist or PPI402.071.4381.959.4−0.1 (−0.9, 0.7) Aspirin with no history of coronary, cerebral or peripheral arterial symptoms or occlusive arterial event40219.6 to 37718.4: −1.2 (−3.9, 1.4) Central nervous system TCAs with an opiate or calcium channel blocker462.2 to 693.4 to 1.1 (0.1, 2.1)** Long-term (>1 month), long-acting benzodiazepines803.934.8643.133.0−0.8 (−1.9, 0.4)* Gastrointestinal System PPI at full therapeutic dosage for >8 weeks35317.242.645021.947.44.7 (2.0, 7.4)*** Musculoskeletal system NSAID with history of PUD, unless with concurrent H2 receptor antagonist, PPI or misoprostol371.877.1412.083.70.2 (−0.6, 1.0) NSAID with moderate-severe hypertension >160/100 mmHgb 1879.133.020710.134.01.0 (−0.9, 2.9) Long-term use of NSAID (>3 months)994.814.21075.216.20.4 (−1.0, 1.8) Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthrtitis/osteorarthritis371.820.6472.320.80.5 (−0.4, 1.4) Drugs that adversely affect fallers Benzodiazepines in those prone to falls633.114.4552.711.4−0.4 (−1.4, 0.6) Neuroleptic drugs in those prone to falls341.77.8492.410.20.7 (−0.1, 1.6) Analgesic drugs Regular opiates for >2 weeks without concurrent use of laxatives1095.390.81035.084.4−0.3 (−1.7, 1.1) Duplicate drug classes Any regular duplicate drug class prescription512.5 to 663.2 to 0.7 (−0.3, 1.8)Beers criteria (2012) Anticholinergics Antispasmodics351.7 to 462.2 to 0.5 (−0.3, 1.4) Central nervous system Tertiary TCAs974.7 to 1195.8 to 1.1 (−0.3, 2.5)* Benzodiazepines, short, intermediate and long acting2019.8 to 1808.8: −1.0 (−2.9,0.8) Non-benzodiazepine (Z-drug) hypnotics, avoid chronic use >90 days482.317.3562.717.40.4 (−0.6, 1.4) Gastrointestinal Metoclopramide221.1 to 422.0 to 1.0 (0.2, 1.7)* Pain Non-COX-selective NSAIDs, avoid chronic use934.512.1813.910.6−0.6 (−1.8, 0.7) Drug-disease interactions Avoid with history of falls/fractures (fracture and fall or > 1 fall or >1 fracture) (total)1246.054.41688.259.22.1 (0.5, 3.8)*** Anticonvulsants201.08.8462.216.21.3 (0.5, 2.0)*** Benzodiazepines643.128.1763.726.80.6 (−0.5, 1.7) Z-drugs422.018.4602.921.10.9 (−0.1, 1.8) SSRIs402.017.5452.215.80.2 (−0.6, 1.1)ACOVE indicators Falls and mobility problems If ≥2 falls (or 1 fall with injury) in previous year discontinue benzodiazepine432.114.9442.112.00.0 (−0.8, 0.9) Hypertension If a vulnerable elder (VE) has HTN discontinue NSAID or COX-2 inhibitorb 793.97.8803.97.10.0 (−1.2, 1.3) Medication Use Discontinue benzodiazepine if taking for >1 month803.934.8643.133.0−0.8 (−1.9, 0.4)* Avoid medication with strong anticholinergic effects24511.9 to 28814.0 to 2.1 (−0.1, 4.3)** In iron-deficiency anaemia, prescribe no more than one low-dose oral iron tablet daily271.320.1432.130.30.8 (0.0, 1.6) ACE angiotensin converting enzyme, COPD chronic obstructive pulmonary disease, COX cyclo-oxygenase, GI gastrointestinal, HTN hypertension, MI myocardial infarction, NSAID non-steroidal anti-inflammatory drug, PPI proton pump inhibitor, PUD peptic ulcer disease, SSRI selective serotonin reuptake inhibitor, TCA tricyclic antidepressant, TIA transient ischaemic attack, VE vulnerable elder*McNemar’s test p < 0.05**McNemar’s test p < 0.01***McNemar’s test p < 0.001 aPrevalence of PIM criteria as a proportion of all participants with the disease or prescribed the drug of interest e.g. prevalence of benzodiazepines for >4 weeks as a proportion of all participants prescribed a benzodiazepine bHypertension defined using objectively measured blood pressure or self-reported hypertension diagnosis with antihypertensive medication Prevalence of individual PPO criteria (prevalence ≥2 %) at baseline and 2-year follow-upBaselineFollow-upCriteria description n % of sample% of indicationa n % of sample% of indicationa Change in prevalence (95 % CI)START Cardiovascular system Warfarin (or another oral anticoagulant) in the presence of chronic atrial fibrillation1547.567.51909.362.91.8 (0.1, 3.4)*** Aspirin/clopidogrel with a history of atherosclerotic coronary, cerebral or peripheral vascular disease482.314.2512.514.60.1 (−0.7, 1.0) Antihypertensive therapy where systolic blood pressure >160 mmHgb 775.531.3493.519.6−2.0 (−3.4, −0.6)*** Statin therapy with a history of coronary, cerebral or peripheral vascular disease673.320.7824.021.80.7 (−0.3, 1.8)* ACE inhibitor following acute MI613.014.6582.811.9−0.1 (−1.0, 0.8) β blocker with chronic stable angina844.137.3813.933.8−0.1 (−1.2, 0.9) Respiratory system Regular inhaled β2 agonist or anticholinergic agent for mild to moderate asthma or COPD1025.037.01165.737.50.7 (−0.6, 2.0) Musculoskeletal system Bisphosphonates if taking oral corticosteroids for >3 months623.060.2713.564.50.4 (−0.5, 1.4) Calcium and vitamin D supplement with osteoporosis30114.757.932916.051.61.4 (−0.9, 3.6)* Endocrine system Antiplatelet therapy in diabetes mellitus if ≥1 major CV risk factor (hypertension, hypercholesterolaemia, smoking history)562.727.6643.128.60.4 (−0.5, 1.4) Statin therapy in diabetes mellitus if ≥1 major CV risk factor502.424.6502.422.31.4 (−0.9, 3.6)ACOVE indicators COPD If a VE has COPD, prescribe a rapid-acting bronchodilator432.140.2663.246.21.1 (0.3, 2.0)*** If a VE with COPD has 2+ exacerbations requiring antibiotics/oral corticosteroids in the previous year, then (in addition to a long-acting bronchodilator) prescribe inhaled steroids (if not taking oral steroids)201.058.8412.063.11.0 (0.4, 1.6) Diabetes If a VE with diabetes mellitus not on anticoagulant or antiplatelet, then daily aspirin should be prescribed542.626.9582.827.20.2 (−0.7, 1.1) Hypertension If a VE with HTN has IHD, prescribe a β blockerc 623.037.1633.134.60.0 (−0.9, 1.0) If a VE with HTN has a history of HF, IHD, chronic kidney disease or CV accident, prescribe an ACE inhibitor/ARBc 663.229.2683.326.80.1 (−0.9, 1.1) Ischaemic heart disease If a VE has had an MI, prescribe a β blocker613.034.5592.930.3−0.1 (−1.0, 0.8) If a VE has IHD, prescribe an ACE inhibitor/ARB813.936.0824.034.20.0 (−1.0, 1.1) Medication use If a VE with a risk factor for GI bleeding (aged ≥75, PUD, warfarin use, chronic glucocorticoid use) is prescribed a non-selective NSAID, treat concomitantly with misoprostol/a PPI20710.168.51828.965.0−1.2 (−3.0, 0.5) Osteoporosis If a VE without osteoporosis is taking ≥7.5 mg/day of prednisone (or equivalent) for ≥1 month, prescribe calcium and vitamin D532.659.6532.657.60.0 (−0.8, 0.8) If a VE has osteoporosis, prescribe calcium and vitamin D supplements30114.757.932916.051.61.4 (−0.9, 3.6) If a female VE has osteoporosis, treat with bisphosphonate, raloxifene, calcitonin, HRT or teriparatide1869.148.924912.153.23.1 (1.2, 4.9)*** If a male VE has osteoporosis, treat with bisphosphonate, calcitonin, parathyroid hormone or testosterone1236.087.91447.085.21.0 (−0.4, 2.5)*** Pain If a VE with persistent pain is treated with opioids, prescribe a stool softener/laxative22511.082.726512.982.02.0 (0.0, 3.9)* Stroke If a VE has had a TIA or stroke, prescribe antiplatelet/anticoagulant therapy834.058.9994.854.40.8 (−0.4, 1.9)** ACE angiotensin converting enzyme, ARB angiotensin II receptor blocker, COPD chronic obstructive pulmonary disease, COX cyclo-oxygenase, CV cardiovascular, GI gastrointestinal, HF heart failure, HRT hormone replacement therapy, HTN hypertension, IHD ischaemic heart disease, MI myocardial infarction, NSAID non-steroidal anti-inflammatory drug, PPI proton pump inhibitor, PUD peptic ulcer disease, TIA transient ischaemic attack, VE vulnerable elder*McNemar’s test p < 0.05**McNemar’s test p < 0.01***McNemar’s test p < 0.001 aPrevalence of PPO criteria as a proportion of all participants with the disease or prescribed the drug of interest e.g. prevalence of ACE inhibitor omission as a proportion of all participants who have had an acute MI bSix hundred sixty-one participants (32.2 %) had missing data for measured blood pressure cHypertension defined using objectively measured blood pressure or self-reported hypertension diagnosis with antihypertensive medication

Source: Prevalence of potentially inappropriate medicine use and potential prescribing omissions. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This is a prospective cohort study of participants aged ≥65 years in The Irish Longitudinal Study on Ageing (TILDA) with linked pharmacy claims data (n = 2051).

Source: Abstract.

This is a prospective cohort study of participants aged ≥65 years in The Irish Longitudinal Study on Ageing (TILDA) with linked pharmacy claims data (n = 2051).

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Longitudinal prevalence of potentially inappropriate medicines and potential prescribing omissions in a cohort of community-dwelling older people

Cohort study · European Journal of Clinical Pharmacology · 2015

Original publication title

Longitudinal prevalence of potentially inappropriate medicines and potential prescribing omissions in a cohort of community-dwelling older people

Frank Moriarty; Kathleen Bennett; Tom Fahey; Rose Anne Kenny; Caitriona Cahir

© The Author(s) 2015

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Sub-optimal prescribing is common in older patients. Ongoing prescribing review to optimise care is important, particularly as patients get older, receive more medicines or develop more illnesses.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

This study aims to compare the prevalence of potentially inappropriate medicines (PIMs) and potential prescribing omissions (PPOs) using several screening tools in an Irish community-dwelling older cohort, to assess if the prevalence changes over time and to determine factors associated with any change.

Source: Purpose

Abstract: What methods does the paper describe?

This is a prospective cohort study of participants aged ≥65 years in The Irish Longitudinal Study on Ageing (TILDA) with linked pharmacy claims data (n = 2051). PIM and PPO prevalence was measured in the year preceding participants’ TILDA baseline interviews and in the year preceding their follow-up interviews using the Screening Tool for Older Persons’ Prescriptions (STOPP), Beers criteria (2012), Assessing Care of Vulnerable Elders (ACOVE) indicators and the Screening Tool to Alert doctors to Right Treatment (START).

Generalised estimating equations were used to determine factors associated with change in prevalence over time.

Source: Methods

Abstract: Electronic supplementary material

The online version of this article (doi:10.1007/s00228-015-1815-1) contains supplementary material, which is available to authorized users.

Source: Electronic supplementary material

Abstract: Results

Depending on the screening tool used, between 19.8 % (ACOVE indicators) and 52.7 % (STOPP) of participants received a PIM at baseline, and PPO prevalence ranged from 38.2 % (START) to 44.8 % (ACOVE indicators), while 36.7 % of participants had both a PIM and PPO. Common criteria were aspirin for primary prevention (19.6 %) and omission of calcium/vitamin D in osteoporosis (14.7 %). Prevalence of PIMs and PPOs increased at follow-up (PIMs range 22 to 56.1 %, PPOs range 40.5 to 49.3 %), and this was associated with patient age, female sex, and numbers of medicines and chronic conditions.

Source: Results

Abstract: Conclusions

Sub-optimal prescribing is common in older patients. Ongoing prescribing review to optimise care is important, particularly as patients get older, receive more medicines or develop more illnesses.

Source: Conclusions
Authors’ abstract

Purpose

This study aims to compare the prevalence of potentially inappropriate medicines (PIMs) and potential prescribing omissions (PPOs) using several screening tools in an Irish community-dwelling older cohort, to assess if the prevalence changes over time and to determine factors associated with any change.

Methods

This is a prospective cohort study of participants aged ≥65 years in The Irish Longitudinal Study on Ageing (TILDA) with linked pharmacy claims data (n = 2051). PIM and PPO prevalence was measured in the year preceding participants’ TILDA baseline interviews and in the year preceding their follow-up interviews using the Screening Tool for Older Persons’ Prescriptions (STOPP), Beers criteria (2012), Assessing Care of Vulnerable Elders (ACOVE) indicators and the Screening Tool to Alert doctors to Right Treatment (START).

Generalised estimating equations were used to determine factors associated with change in prevalence over time.

Results

Depending on the screening tool used, between 19.8 % (ACOVE indicators) and 52.7 % (STOPP) of participants received a PIM at baseline, and PPO prevalence ranged from 38.2 % (START) to 44.8 % (ACOVE indicators), while 36.7 % of participants had both a PIM and PPO. Common criteria were aspirin for primary prevention (19.6 %) and omission of calcium/vitamin D in osteoporosis (14.7 %). Prevalence of PIMs and PPOs increased at follow-up (PIMs range 22 to 56.1 %, PPOs range 40.5 to 49.3 %), and this was associated with patient age, female sex, and numbers of medicines and chronic conditions.

Conclusions

Sub-optimal prescribing is common in older patients. Ongoing prescribing review to optimise care is important, particularly as patients get older, receive more medicines or develop more illnesses.

Electronic supplementary material

The online version of this article (doi:10.1007/s00228-015-1815-1) contains supplementary material, which is available to authorized users.

Publication and source details

Original title: Longitudinal prevalence of potentially inappropriate medicines and potential prescribing omissions in a cohort of community-dwelling older people

Frank Moriarty; Kathleen Bennett; Tom Fahey; Rose Anne Kenny; Caitriona Cahir

European Journal of Clinical Pharmacology · 2015

© The Author(s) 2015https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T10:56:32.198660+00:00

DOI: 10.1007/s00228-015-1815-1 · PMC4356885